Literature DB >> 19142985

Using DCE and ranking data to estimate cardinal values for health states for deriving a preference-based single index from the sexual quality of life questionnaire.

Julie Ratcliffe1, John Brazier, Aki Tsuchiya, Tara Symonds, Martin Brown.   

Abstract

There is an increasing interest in using data derived from ordinal methods, particularly data derived from discrete choice experiments (DCEs), to estimate the cardinal values for health states to calculate quality adjusted life years (QALYs). Ordinal measurement strategies such as DCE may have considerable practical advantages over more conventional cardinal measurement techniques, e.g. time trade-off (TTO), because they may not require such a high degree of abstract reasoning. However, there are a number of challenges to deriving the cardinal values for health states using ordinal data, including anchoring the values on the full health-dead scale used to calculate QALYs. This paper reports on a study that deals with these problems in the context of using two ordinal techniques, DCE and ranking, to derive the cardinal values for health states derived from a condition-specific sexual health measure. The results were compared with values generated using a commonly used cardinal valuation technique, the TTO. This study raises some important issues about the use of ordinal data to produce cardinal health state valuations. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19142985     DOI: 10.1002/hec.1426

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  27 in total

1.  Health utility elicitation: is there still a role for direct methods?

Authors:  Lisa A Prosser; Scott D Grosse; Eve Wittenberg
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

2.  Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale.

Authors:  John Brazier; Donna Rowen; Yaling Yang; Aki Tsuchiya
Journal:  Eur J Health Econ       Date:  2011-09-30

3.  Values for health states with different life durations.

Authors:  Luciana Scalone; Peep F M Stalmeier; Silvano Milani; Paul F M Krabbe
Journal:  Eur J Health Econ       Date:  2014-09-30

Review 4.  Reconceptualising the external validity of discrete choice experiments.

Authors:  Emily Lancsar; Joffre Swait
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

Review 5.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.

Authors:  Donna Rowen; John Brazier; Roberta Ara; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

6.  Dealing with the health state 'dead' when using discrete choice experiments to obtain values for EQ-5D-5L heath states.

Authors:  Juan Manuel Ramos-Goñi; Oliver Rivero-Arias; María Errea; Elly A Stolk; Michael Herdman; Juan Manuel Cabasés
Journal:  Eur J Health Econ       Date:  2013-07

7.  Exclusion Criteria as Measurements I: Identifying Invalid Responses.

Authors:  Barry Dewitt; Baruch Fischhoff; Alexander L Davis; Stephen B Broomell; Mark S Roberts; Janel Hanmer
Journal:  Med Decis Making       Date:  2019-08-28       Impact factor: 2.583

8.  Developing adolescent-specific health state values for economic evaluation: an application of profile case best-worst scaling to the Child Health Utility 9D.

Authors:  Julie Ratcliffe; Terry Flynn; Frances Terlich; Katherine Stevens; John Brazier; Michael Sawyer
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

Review 9.  Outcome measurement in economic evaluations of public health interventions: a role for the capability approach?

Authors:  Paula K Lorgelly; Kenny D Lawson; Elisabeth A L Fenwick; Andrew H Briggs
Journal:  Int J Environ Res Public Health       Date:  2010-05-06       Impact factor: 3.390

Review 10.  Discrete choice experiments in health economics: a review of the literature.

Authors:  Michael D Clark; Domino Determann; Stavros Petrou; Domenico Moro; Esther W de Bekker-Grob
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.